Aurinia Pharmaceuticals Inc

12.80-0.1600-1.23%Vol 1.12M1Y Perf -15.68%
Apr 9th, 2021 16:00 DELAYED
BID12.72 ASK12.79
Open13.00 Previous Close12.96
Pre-Market- After-Market12.77
 - -  -0.03 -0.23%
Target Price
29.75 
Analyst Rating
Strong Buy 1.16
Potential %
132.42 
Finscreener Ranking
★★★★★     69.61
Insiders Trans % 3/6/12 mo.
33/33/33 
Value Ranking
★★★★+     59.57
Insiders Value % 3/6/12 mo.
-74/-74/-74 
Growth Ranking
★★★★★     70.88
Insiders Shares Cnt. % 3/6/12 mo.
-74/-74/-74 
Income Ranking
 —    -
Market Cap1.63B 
Earnings Rating
Sell
Price Range Ratio 52W %
9.31 
Earnings Date
13th May 2021

Today's Price Range

12.6913.00

52W Range

12.0120.50

5 Year PE Ratio Range

-8.30-8.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.59%
1 Month
-2.36%
3 Months
-4.48%
6 Months
-18.37%
1 Year
-15.68%
3 Years
137.48%
5 Years
349.12%
10 Years
-

TickerPriceChg.Chg.%
AUPH12.80-0.1600-1.23
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
12.50
13.10
0.02
0.02
-471.00
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-0.40
-194.50
-191.80
-14 421.50
-
RevenueValueIndustryS&P 500US Markets
50.92M
0.40
299.88
125.80
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.31-0.0583.87
Q03 2020-0.22-0.28-27.27
Q02 2020-0.23-0.26-13.04
Q01 2020-0.20-0.1525.00
Q04 2019-0.21-0.29-38.10
Q03 2019-0.19-0.21-10.53
Q02 2019-0.15-0.17-13.33
Q01 2019-0.16-0.160.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.34-36.00Negative
6/2021 QR-0.30-130.77Negative
12/2021 FY-1.09-25.29Negative
12/2022 FY-0.2125.00Positive
Next Report Date13th May 2021
Estimated EPS Next Report-0.34
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.12M
Shares Outstanding127.45M
Trades Count7.69K
Dollar Volume91.48M
Avg. Volume4.47M
Avg. Weekly Volume1.08M
Avg. Monthly Volume2.79M
Avg. Quarterly Volume4.62M

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 12.8 per share at the end of the most recent trading day (a -1.23% change compared to the prior day closing price) with a volume of 1.16M shares and market capitalization of 1.63B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.

The one-year performance of Aurinia Pharmaceuticals Inc stock is -15.68%, while year-to-date (YTD) performance is -7.45%. AUPH stock has a five-year performance of 349.12%. Its 52-week range is between 12.01 and 20.5, which gives AUPH stock a 52-week price range ratio of 9.31%

Aurinia Pharmaceuticals Inc currently has a PE ratio of -14.50, a price-to-book (PB) ratio of 4.05, a price-to-sale (PS) ratio of 32.89, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.14%, a ROC of -59.59% and a ROE of -28.02%. The company’s profit margin is -%, its EBITDA margin is -191.80%, and its revenue ttm is $50.92 Million , which makes it $0.40 revenue per share.

Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.16), with a target price of $29.75, which is +132.42% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 12.96, ATR14 : 0.94, CCI20 : -111.89, Chaikin Money Flow : -0.08, MACD : -0.61, Money Flow Index : 38.72, ROC : -14.08, RSI : 36.65, STOCH (14,3) : 26.37, STOCH RSI : 0.40, UO : 49.92, Williams %R : -73.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George M. Milne (Buy at a value of $65 000), Neil Solomons (Option Excercise at a value of $120 800), Neil Solomons (Sold 40 000 shares of value $539 600 ), Stephen P. Robertson (Buy at a value of $14 526)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (12.50 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.16
Strong Buy
1.16
Strong Buy
1.19

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

CEO: Peter S. Greenleaf

Telephone: +1 250 708-4272

Address: 4464 Markham Street, Victoria V8Z 7X8, BC, CA

Number of employees: 294

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

55%45%

Bearish Bullish

58%42%

News

Stocktwits